Skip to main content
Top
Published in: Clinical Sarcoma Research 1/2015

Open Access 01-12-2015 | Case Report

Alveolar rhabdomyosarcoma confined to the bone marrow with no identifiable primary tumour using FDG-PET/CT

Authors: Panagiotis Karagiannis, Nina Guth, Gabriela B. Thoennissen, Christina Bern, Jan Sperveslage, Ilske Oschlies, Carsten Bokemeyer, Wolfram Klapper, Eva Wardelmann, Nils H. Thoennissen

Published in: Clinical Sarcoma Research | Issue 1/2015

Login to get access

Abstract

Background

Rhabdomyosarcoma (RMS), a malignant tumour of mesenchymal origin which can occur at various sites in the body, is one of the most common soft tissue sarcomas in both children and adolescents, but is rare in adults with a prevalence of less than 1 %. The alveolar subtype of rhabdomyosarcoma (ARMS) is typically characterized by a specific reciprocal chromosomal translocation involving the PAX3 and FKHR or PAX7 and FKHR genes, respectively. ARMS is most frequently seen in childhood, and typically affects the sinuses and soft tissue of the extremities, with approximately 23 % exhibiting metastasis to the marrow. Non-invasive F-18-fluorodeoxyglucose positron-emission tomography (FDG-PET) scans have a high ability to detect lymph nodes, bone, and bone marrow involvement in patients with metastatic RMS, often with higher sensitivity and specificity compared with conventional modalities.

Case presentation

Here, we report an unusual case of ARMS confined to the bone marrow in an older adult that lacked an identifiable primary tumour using FDG-PET/CT and mimicked a haematological disease with pancytopenia but without abnormal findings by FDG-PET/CT. The patient was initially treated with topotecan/cyclophosphamide and subsequently switched to vinorelbine. Due to severe toxicity the treatment was discontinued, however after 7-months follow-up, the patient is still alive with an improved general state of health and only a mild pancytopenia with no need for blood transfusions.

Conclusion

Rhabdomyosarcoma can be limited to the bone marrow with no identifiable primary tumour. This case shows that the use of a bone marrow biopsy in suspected malignancies affecting the bone marrow is irreplaceable.
Literature
1.
go back to reference Meza JL, Anderson J, Pappo AS, Meyer WH. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: The Children’s Oncology Group. J Clin Oncol. 2006;24(24):3844–51.CrossRefPubMed Meza JL, Anderson J, Pappo AS, Meyer WH. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: The Children’s Oncology Group. J Clin Oncol. 2006;24(24):3844–51.CrossRefPubMed
2.
go back to reference Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from The Children’s Oncology Group. J Clin Oncol. 2002;20(11):2672–9.CrossRefPubMed Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from The Children’s Oncology Group. J Clin Oncol. 2002;20(11):2672–9.CrossRefPubMed
3.
go back to reference Weiss AR, Lyden ER, Anderson JR, Hawkins DS, Spunt SL, Walterhouse DO, et al. Histologic and clinical characteristics can guide staging evaluations for children and adolescents with rhabdomyosarcoma: a report from the children’s oncology group soft tissue sarcoma committee. J Clin Oncol. 2013;31(26):3226–32.PubMedCentralCrossRefPubMed Weiss AR, Lyden ER, Anderson JR, Hawkins DS, Spunt SL, Walterhouse DO, et al. Histologic and clinical characteristics can guide staging evaluations for children and adolescents with rhabdomyosarcoma: a report from the children’s oncology group soft tissue sarcoma committee. J Clin Oncol. 2013;31(26):3226–32.PubMedCentralCrossRefPubMed
4.
go back to reference Tateishi U, Hosono A, Makimoto A, Nakamoto Y, Kaneta T, Fukuda H, et al. Comparative study of FDG PET/CT and conventional imaging in staging rhabdomyosarcoma. Ann Nucl Med. 2009;23(2):155–61.CrossRefPubMed Tateishi U, Hosono A, Makimoto A, Nakamoto Y, Kaneta T, Fukuda H, et al. Comparative study of FDG PET/CT and conventional imaging in staging rhabdomyosarcoma. Ann Nucl Med. 2009;23(2):155–61.CrossRefPubMed
5.
go back to reference Völker T, Denecke T, Steffen I, Misch D, Schönberger S, Plotkin M, et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol. 2007;25(34):5435–41.CrossRefPubMed Völker T, Denecke T, Steffen I, Misch D, Schönberger S, Plotkin M, et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol. 2007;25(34):5435–41.CrossRefPubMed
6.
go back to reference Norman G, Fayter D, Lewis-Light K, Chisholm J, McHugh K, Levine D, et al. An emerging evidence base for PET-CT in the management of childhood rhabdomyosarcoma: systematic review. BMJ Open. 2015;5(1):e006030.PubMedCentralCrossRefPubMed Norman G, Fayter D, Lewis-Light K, Chisholm J, McHugh K, Levine D, et al. An emerging evidence base for PET-CT in the management of childhood rhabdomyosarcoma: systematic review. BMJ Open. 2015;5(1):e006030.PubMedCentralCrossRefPubMed
7.
go back to reference Egas-Bejar D, Huh WW. Rhabdomyosarcoma in adolescent and young adult patients: current perspectives. Adolesc Health Med Ther. 2014;5:115–25.PubMedCentralPubMed Egas-Bejar D, Huh WW. Rhabdomyosarcoma in adolescent and young adult patients: current perspectives. Adolesc Health Med Ther. 2014;5:115–25.PubMedCentralPubMed
8.
go back to reference Ruymann FB, Newton WA Jr, Ragab AH, Donaldson MH, Foulkes M. Bone marrow metastases at diagnosis in children and adolescents with rhabdomyosarcoma. A report from the intergroup rhabdomyosarcoma study. Cancer. 1984;53(2):368–73.CrossRefPubMed Ruymann FB, Newton WA Jr, Ragab AH, Donaldson MH, Foulkes M. Bone marrow metastases at diagnosis in children and adolescents with rhabdomyosarcoma. A report from the intergroup rhabdomyosarcoma study. Cancer. 1984;53(2):368–73.CrossRefPubMed
9.
go back to reference Messiou C, Kaiser M. Whole body diffusion weighted MRI—a new view of myeloma. Br J Haematol. 2015;171(1):29–37.CrossRefPubMed Messiou C, Kaiser M. Whole body diffusion weighted MRI—a new view of myeloma. Br J Haematol. 2015;171(1):29–37.CrossRefPubMed
Metadata
Title
Alveolar rhabdomyosarcoma confined to the bone marrow with no identifiable primary tumour using FDG-PET/CT
Authors
Panagiotis Karagiannis
Nina Guth
Gabriela B. Thoennissen
Christina Bern
Jan Sperveslage
Ilske Oschlies
Carsten Bokemeyer
Wolfram Klapper
Eva Wardelmann
Nils H. Thoennissen
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Clinical Sarcoma Research / Issue 1/2015
Electronic ISSN: 2045-3329
DOI
https://doi.org/10.1186/s13569-015-0039-6

Other articles of this Issue 1/2015

Clinical Sarcoma Research 1/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine